Catalyst Biosciences Revenue | CBIO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Catalyst Biosciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
117 M	106 M	113 M	102 M	-	20.9 M	-	6 K	1.02 M	399 K	1.75 M	275 K	3.63 M	57.9 M	97.6 M	85.7 M	25.1 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
117 M	6 K	48.8 M

Quarterly Revenue Catalyst Biosciences

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
29.1 M	22.5 M	30.6 M	26.8 M	22.1 M	-	25.5 M	25.2 M	27.2 M	-	32 M	29.3 M	24.9 M	-	-	-	794 K	-	2.3 M	1.13 M	1.47 M	-	893 K	1.66 M	16.4 M	-	-	-	-	-	6 K	6 K	6 K	-	318 K	111 K	-	-	-	-	-	-	-	-	60 K	127 K	25 K	36 K	87 K	93 K	3.54 M	3.54 M	3.54 M	590 K	768 K	33.6 M	22.9 M	18.9 M	19 M	20.7 M	39 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
39 M	6 K	12.2 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	53 M	$ 51.7	1.83 %	$ 1.5 B	USA
Bicycle Therapeutics plc BCYC	72.6 M	$ 3.73	3.61 %	$ 258 M	Britain
Black Diamond Therapeutics BDTX	70 M	$ 1.89	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	36 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	32.6 M	-	-	$ 401 M	USA
BioLineRx Ltd. BLRX	1.18 M	$ 2.52	1.17 %	$ 6.21 B	Israel
BioMarin Pharmaceutical BMRN	3.22 B	$ 61.35	0.06 %	$ 11.8 B	USA
Benitec Biopharma BNTC	75 K	$ 9.64	0.46 %	$ 449 M	USA
BioNTech SE BNTX	482 M	$ 99.26	0.81 %	$ 24 B	Germany
Genocea Biosciences GNCA	1.64 M	-	-15.0 %	$ 3.04 M	USA
Burford Capital Limited BUR	413 M	$ 3.63	3.93 %	$ 795 M	Britain
Amryt Pharma plc AMYT	223 M	-	-	$ 621 M	Britain
G1 Therapeutics GTHX	82.5 M	-	-	$ 370 M	USA
Can-Fite BioPharma Ltd. CANF	405 K	$ 2.17	0.46 %	$ 3.57 M	Israel
C4 Therapeutics CCCC	35.9 M	$ 3.03	0.3 %	$ 251 M	USA
Codexis CDXS	70.4 M	$ 1.37	1.45 %	$ 119 M	USA
Cerus Corporation CERS	234 M	$ 2.61	0.38 %	$ 497 M	USA
AbbVie ABBV	16.6 B	$ 265.12	0.09 %	$ 469 B	USA
Humanigen HGEN	2.51 M	-	-81.12 %	$ 4.28 M	USA
Coherus BioSciences CHRS	42.2 M	$ 1.17	1.48 %	$ 137 M	USA
AbCellera Biologics ABCL	75.1 M	$ 12.65	2.76 %	$ 3.78 B	Canada
Abeona Therapeutics ABEO	5.82 M	$ 5.43	2.65 %	$ 288 M	USA
Celldex Therapeutics CLDX	1.54 M	$ 31.48	1.16 %	$ 2.09 B	USA
CollPlant Biotechnologies Ltd. CLGN	2.37 M	$ 4.12	1.98 %	$ 50.3 M	Israel
Фармсинтез LIFE	372 M	-	-	-	Russia
IMV IMV	188 K	-	-	$ 13.1 M	Canada
Karuna Therapeutics KRTX	654 K	-	-	$ 12.2 B	USA
Cocrystal Pharma COCP	2.01 M	$ 1.15	1.67 %	$ 13 M	USA
Crinetics Pharmaceuticals CRNX	7.7 M	$ 84.95	0.13 %	$ 7.99 B	USA
Collegium Pharmaceutical COLL	205 M	$ 22.64	0.85 %	$ 717 M	USA
Corcept Therapeutics Incorporated CORT	761 M	$ 118.51	4.93 %	$ 12.3 B	USA
Chimerix CMRX	212 K	-	-	$ 756 M	USA
Corbus Pharmaceuticals Holdings CRBP	882 K	$ 7.45	0.19 %	$ 99.2 M	USA
Curis CRIS	9.44 M	$ 0.88	0.85 %	$ 11.6 M	USA
CorMedix CRMD	312 M	$ 7.77	1.04 %	$ 560 K	USA
CRISPR Therapeutics AG CRSP	3.51 M	$ 55.7	0.23 %	$ 5.01 B	Schweiz
Champions Oncology CSBR	59.4 M	$ 4.95	0.38 %	$ 68.5 M	USA
Arbutus Biopharma Corporation ABUS	14.1 M	$ 4.88	0.62 %	$ 935 M	Canada
Cue Biopharma CUE	27.5 M	$ 32.85	3.6 %	$ 3.11 B	USA
CEL-SCI Corporation CVM	255 K	$ 1.72	2.38 %	$ 13.8 M	USA